JPWO2022258673A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022258673A5 JPWO2022258673A5 JP2023575753A JP2023575753A JPWO2022258673A5 JP WO2022258673 A5 JPWO2022258673 A5 JP WO2022258673A5 JP 2023575753 A JP2023575753 A JP 2023575753A JP 2023575753 A JP2023575753 A JP 2023575753A JP WO2022258673 A5 JPWO2022258673 A5 JP WO2022258673A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- polypeptide chain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208514P | 2021-06-09 | 2021-06-09 | |
| US63/208,514 | 2021-06-09 | ||
| PCT/EP2022/065514 WO2022258673A1 (en) | 2021-06-09 | 2022-06-08 | Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024521408A JP2024521408A (ja) | 2024-05-31 |
| JPWO2022258673A5 true JPWO2022258673A5 (https=) | 2025-06-16 |
| JP2024521408A5 JP2024521408A5 (https=) | 2025-06-16 |
Family
ID=82214258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575753A Pending JP2024521408A (ja) | 2021-06-09 | 2022-06-08 | Ｃｄ２０、ｎｋｐ４６、ｃｄ１６に結合し、かつｉｌ－２にコンジュゲートされた多特異性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002601A1 (https=) |
| EP (1) | EP4351733A1 (https=) |
| JP (1) | JP2024521408A (https=) |
| KR (1) | KR20240019786A (https=) |
| CN (1) | CN117529504A (https=) |
| AU (1) | AU2022288574A1 (https=) |
| BR (1) | BR112023025476A2 (https=) |
| CA (1) | CA3227227A1 (https=) |
| IL (1) | IL308531A (https=) |
| MX (1) | MX2023014645A (https=) |
| WO (1) | WO2022258673A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024251884A1 (en) | 2023-06-09 | 2024-12-12 | Innate Pharma | Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl |
| US20250122299A1 (en) * | 2023-08-28 | 2025-04-17 | Xencor, Inc. | ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES |
| WO2025168114A1 (en) * | 2024-02-09 | 2025-08-14 | Shanghai Epimab Biotherapeutics Co., Ltd. | Multifunctional nk cell engager |
| WO2026055280A1 (en) * | 2024-09-04 | 2026-03-12 | Sanofi | Interleukin 2 (il-2) and cd123 nk cell engager combination therapy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0981548A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| JP2004126818A (ja) | 2002-09-30 | 2004-04-22 | Toshiba Corp | 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法 |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| SG173322A1 (en) | 2004-04-16 | 2011-08-29 | Macrogenics Inc Dw Us | Fc gammad riib - specific antibodies and methods of use thereof |
| WO2005110474A2 (en) | 2004-05-10 | 2005-11-24 | Macrogenics, Inc. | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| US20090208500A1 (en) | 2005-06-03 | 2009-08-20 | Genentech, Inc. | Method of producing antibodies with improved function |
| HUE029465T2 (en) | 2005-08-10 | 2017-02-28 | Macrogenics Inc | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| CA2644903A1 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
| US7786270B2 (en) | 2006-05-26 | 2010-08-31 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
| WO2008002933A2 (en) | 2006-06-26 | 2008-01-03 | Macrogenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| EP2658869B1 (en) | 2010-12-30 | 2019-06-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigen binding formats for use in therapeutic treatments or diagnostic assays |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| RU2682449C2 (ru) | 2012-09-19 | 2019-03-19 | Иннейт Фарма | Связывающие kir3dl2 агенты |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| WO2016207278A1 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific nk engager proteins |
| CN115925933A (zh) | 2015-12-28 | 2023-04-07 | 依奈特制药公司 | NKp46结合蛋白的可变区 |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| AU2018300069C1 (en) | 2017-07-11 | 2025-11-20 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
| WO2019028419A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES |
| WO2020057646A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| AU2020287373B2 (en) | 2019-06-05 | 2026-01-29 | Asher Biotherapeutics, Inc. | Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function |
| CA3143034A1 (en) | 2019-06-14 | 2020-12-17 | Cugene Inc. | Novel interleukin-2 variants for the treatment of cancer |
-
2022
- 2022-06-08 US US18/568,806 patent/US20250002601A1/en active Pending
- 2022-06-08 IL IL308531A patent/IL308531A/en unknown
- 2022-06-08 WO PCT/EP2022/065514 patent/WO2022258673A1/en not_active Ceased
- 2022-06-08 JP JP2023575753A patent/JP2024521408A/ja active Pending
- 2022-06-08 MX MX2023014645A patent/MX2023014645A/es unknown
- 2022-06-08 CA CA3227227A patent/CA3227227A1/en active Pending
- 2022-06-08 EP EP22733563.5A patent/EP4351733A1/en active Pending
- 2022-06-08 AU AU2022288574A patent/AU2022288574A1/en active Pending
- 2022-06-08 BR BR112023025476A patent/BR112023025476A2/pt unknown
- 2022-06-08 CN CN202280041605.8A patent/CN117529504A/zh active Pending
- 2022-06-08 KR KR1020237045295A patent/KR20240019786A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210269502A1 (en) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment | |
| DK173543B1 (da) | Modent humant leukocytinterferon; en bakterie, der kan producere et sådant interferon, og en fremgangsmåde til fremstilling | |
| AU2024202988A1 (en) | Interleukin-2-Fc fusion proteins and methods of use | |
| KR860001558B1 (ko) | 인터페론의 제조방법 | |
| Takatsu et al. | Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. | |
| Leutz et al. | Molecular cloning of the chicken myelomonocytic growth factor (cMGF) reveals relationship to interleukin 6 and granulocyte colony stimulating factor. | |
| Youvan et al. | Light-harvesting II (B800-B850 complex) structural genes from Rhodopseudomonas capsulata | |
| Labriola-Tompkins et al. | Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor. | |
| US10738096B2 (en) | Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities | |
| JPS63299A (ja) | ヒトｇ−ｃｓｆタンパク質の発現 | |
| Wilson et al. | Clustering of cytokine genes on mouse chromosome 11. | |
| CN112961248B (zh) | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 | |
| US11542318B2 (en) | Use of chemokine receptor CXCR5 | |
| JPWO2022258673A5 (https=) | ||
| WO2022007795A1 (zh) | 一种嵌合受体及其应用 | |
| CN118546233B (zh) | 白介素-21突变体及其应用 | |
| JPWO2020124273A5 (https=) | ||
| CN107254482A (zh) | 一种提高重组猪干扰素‑α融合蛋白抗病毒活性的方法 | |
| US20250223330A1 (en) | Designed cytokine compositions and methods of use | |
| CN108753773A (zh) | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 | |
| CN116239692B (zh) | 分离的抗体、包含该抗体的car及其用途 | |
| Lu et al. | Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics | |
| CN107435045B (zh) | 一种优化重组人白细胞介素-2的核苷酸序列及高效可溶性表达方法 | |
| CN110669770A (zh) | 人源化单克隆抗体、其制备方法及其用途 | |
| CN107217068A (zh) | 一种提高重组犬干扰素‑α融合蛋白抗病毒活性的方法 |